Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 733-737 , December 2009

Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes

Received 4 February 2009 ,Revised 8 July 2009 ,Accepted 12 July 2009.

References 

  1. Ljungberg B, Hanbury D, Kuczyk M. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502–1510
  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.1.2008. National Comprehensive Cancer Network: http://www.nccn.org/professionals/physician_gls/PDF/kidneypdf [serial online] 2008. URL: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
  3. Godley P, Taylor M. Renal cell carcinoma. Curr Opin Oncol. 2001;13:199–203
  4. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193–205
  5. Sachdeva K, Makhoul I, Javeed M, Curti B. Renal cell carcinoma. eMedicine [serial online] 2006. http://www.emedicine.com/MED/topic2002.htm:1-23 URL: http://www.emedicine.com/MED/topic2002.htm.
  6. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews 2004; 3: Art. No.: CD001425. doi:10.1002/14651858. CD001425.pub2.
  7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  8. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–2111
  9. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  10. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  11. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;[Epub ahead of print 10.1200/JCO.2008.20.1293]
  12. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113
  13. Wagner LI, Wenzel L, Shaw E, Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol. 2007;25:5058–5062
  14. Harding G, Cella D, Robinson D, Mahadevia PJ, Clark J, Revicki DA. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes. 2007;5:34–45
  15. Medical Research Council Renal Cancer Collaborators . Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14–17
  16. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  17. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79
  18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  19. Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004;13:137–154
  20. de Boer AG, van Lanschot JJ, Stalmeier PF, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?. Qual Life Res. 2004;13:311–320
  21. EuroQol . EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199–208
  22. Cella D, Yount S, Du H, et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol. 2006;4:191–199
  23. Cella D, Yount S, Brucker PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007;10:285–293
  24. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008;26:3763–3769
  25. Bayer Heathcare AG. Nexavar, Summary of product characteristics; 2007.
  26. Bukowski R, Szczylik C, Stadler W, Simantov R, Shan M. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol. 2007;25(18S):240s;[Abstract 5023 (abstr)]
  27. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30:220–227
  28. Szczylik C, Cella D, Eisen T, et al. Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-a (IFN). In: Poster presented at the 44th annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, 2008; [Abstract 9603. Ref Type: Unpublished Work].
  29. Wyeth Pharmaceuticals, Inc. Torisel summary of product characteristics; 2007.
  30. Parasuraman P, Hudes G, Levy DE, Strahs A, Moore L, DeMarinis R. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-a (IFN) or the combination of IFN+TEMSR. J Clin Oncol. 2007;25(18S):247S;[abstract 5049 (poster presentation) (abstr)]
  31. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975–984
  32. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol. 2008;47:843–851
  33. Amato R, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2006;24(18S Part 1):224s–4530
  34. Jac J, Giessinger S, Khan MA, et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol: Official J Am Soc Clin Oncol. 2007;25:[Ref Type: Unpublished Work]
  35. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456

PII: S0305-7372(09)00097-8

doi: 10.1016/j.ctrv.2009.07.003

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 733-737 , December 2009

Article Tools

* Image Usage & Resolution